Impact of cytochrome P450 3A5 expression on clinical outcomes in renal transplant recipients receiving tacrolimus-based immunosuppression

Table 2 Association of cytochrome P450 3A5 polymorphism with tacrolimus doses in expressors and non-expressors

Timeline	Expressors (n = 35) (mean ± SD)	Non-expressors (n = 60) (mean ± SD)	P value
Tacrolimus dose (mg/kg)
At 5 days	0.08 ± 0.14	0.05 ± 0.02	0.1049
At 15 days	0.05 ± 0.03	0.05 ± 0.03	-
At 30 days	0.05 ± 0.03	0.05 ± 0.03	-
At 45 days	0.06 ± 0.03	0.05 ± 0.03	0.1205
At 90 days	0.06 ± 0.03	0.05 ± 0.03	0.1205
At 120 days	0.06 ± 0.03	0.05 ± 0.03	0.1205
At 6 months	0.06 ± 0.03	0.04 ± 0.03	0.002
At 9 months	0.06 ± 0.02	0.05 ± 0.03	0.082
At 12 months	0.06 ± 0.01	0.04 ± 0.03	0.002